cyrilzakka/clinical-trials huggingface dataset:
Changes in Seroprevalence and Wellness Over Time in Healthcare Workers (CONSERVE-HCW)

The Investigators propose a multi-center, observational, longitudinal, cohort study of the serology and wellness of HCWs over a year of the COVID-19 pandemic.

All consenting participants will undergo survey assessment and diagnostic testing with the Abbott Architect SARS-CoV-2 IgG assay (IgG) every three months for a one year period. Clinical outcomes and related data capture will be performed at this same interval.

Eligibility Criteria:
Inclusion Criteria:

1. Age greater than or equal to 18 years; and
2. Be an active member of the CommonSpirit Health workforce or medical staff during the COVID-19 pandemic and at the time of enrollment; and
3. Have access to the Internet; and
4. The ability to provide informed consent.

Exclusion Criteria:

1. Subjects that lack the ability for longitudinal follow-up; and/or
2. Subjects that do not meet the above inclusion criteria. -
Outpatient Laparoscopic Radical Prostatectomy

The purpose of the study is to evaluate the incidence of surgery-related complications between Day 0 and Day 30.

This is an observational, prospective, open, non-comparative (single arm), bicentric study.

This study is aimed at patients with prostate cancer for whom an ambulatory laparoscopic radical prostatectomy has been validated at a multidisciplinary consultation meeting. The possibility of performing this procedure on an outpatient basis is left to the surgeon's discretion, according to well-defined medical procedure criteria.

This cohort is part of the usual care. The study will observe the incidence and describe the type, number, severity, duration and frequency of procedure-related complications that may arise in the first month post-op of ambulatory Laparoscopic Radical Prostatectomy. For this reason, patient follow-up will stop at 1 month after surgery, during a routine follow-up visit.

Eligibility Criteria:
Inclusion Criteria:

* Male, age ≥ 18 years;
* Localized prostate cancer;
* Validation in a multidisciplinary consultation meeting of curative treatment;
* Scheduled laparoscopic radical prostatectomy;
* Patient able to understand the information related to the study, to read the information leaflet and to signify his/her non-opposition or opposition to participating in the study;
* Membership of a social security scheme;
* Patient having been informed and having given oral non-opposition.

Exclusion Criteria:

* Surgical emergency;
* Patient not eligible for ambulatory care;
* Long-term curative anti-coagulant treatment;
* Resident more than 100km from the clinic;
* Home alone the first night;
* Patient under guardianship, curatorship or deprivation of liberty.
Comparison Between Laryngoscope McCoy With Macintosh

This study aimed to compare cardiovascular response and ease of intubation using laryngoscope McCoy with Macintosh

Eighty-two subjects were given informed consent before enrolling the study and randomized into two groups: McCoy and Macintosh. Non-invasive blood pressure

Eligibility Criteria:
Inclusion Criteria :

* adults (18 - 65 years old)
* body mass index 18,5 - 30 kg/m2
* physical status with ASA 1 -2
* patients who agreed to participate in this study and sign informed consent.

Exclusion Criteria:

* pregnancy
* history of infarct miocard
* right or left heart failure
* P-R interval 0,24 seconds
* heart block degree 2 or 3
* using pace maker
* history of cerebrovascular disease
* tachycardia or bradycardia
* on medication (antiarrhythmic drugs, beta blocker, heart stimulant)
* suspect difficult airways
* including ventilation (assesment with MOANS) or intubation (assesment with LEMONS)
* patients with increase of intracranial pressure (e.g.head injury)
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of gemcitabine given directly into the bladder in treating patients who have recurrent or refractory bladder cancer.

OBJECTIVES: I. Determine the maximum tolerated dose of intravesical gemcitabine in patients with recurrent or refractory superficial bladder cancer. II. Determine the dose-limiting toxicity and other toxic effects of this regimen in these patients. III. Assess any responses in patients treated with this regimen.

OUTLINE: This is a dose-escalation, multicenter study. Patients receive intravesical gemcitabine that is left in the bladder for 2 hours and then removed on day 1. Treatment continues every 7 days for 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of intravesical gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 3-36 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed stage Tis, Ta, or T1 bladder carcinoma No stage B1 disease or greater No locally invasive or metastatic disease by CT or MRI No upper urinary tract disease Measurable persistent or recurrent superficial disease after standard treatment with intravesical BCG Stage Tis disease must fail second course of BCG if complete response achieved with first course of BCG Prior maximal transurethral resection High-grade T1 or Tis disease must be ineligible for cystectomy

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL AST no greater than 2 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL Other: Not pregnant Negative pregnancy test Fertile patients must use effective contraception for 1 week prior to, during, and for at least 2 weeks after study No active bacterial infection requiring treatment with antibiotics

PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 4 weeks since prior immunotherapy Chemotherapy: Prior intravesical chemotherapy allowed At least 4 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior radiotherapy No prior radiotherapy to bladder Surgery: See Disease Characteristics At least 2 weeks since prior transurethral resection of the bladder/bladder biopsy
Efficacy and Safety of Fractional Carbon Dioxide Laser for Treatment of Facial Freckles.

Freckles are clusters of melanin in the superficial epidermis. They affect mostly face and sun exposed areas, and appear as flat brown or red macules that fade in winter, usually in a fair complexion patient, but may be present in other skin types.

The gold standard in the industry for non-surgical facial rejuvenation, removal of wrinkles, pigmentation, and general sun damage has been the carbon dioxide (CO2) laser since the mid 1990s. The traditional CO2 laser was very effective, however it fell out of favor because it required general anesthesia. It also had a prolonged recovery time. Over the last several years, advances in technology known as fractional resurfacing has made the CO2 laser popular again: Fractional CO2 laser treatment is one of the newest laser rejuvenation technology. It proved successful in treatment of melasma, one of the pigmented dermatoses. To the best of our knowledge, based on a thorough search of literature, no clinical studies assessing fractional CO2 laser in treatment of freckles could be retrieved.


Eligibility Criteria:
Inclusion Criteria:

* -Patients affected with facial freckles.
* Age: 10 years or more

Exclusion Criteria:

* Patients younger than 10 years old.
* Patients aged 10-21 years who can not provide a written consent of parents or legal guardian.
* Patients with known tendency to keloid or hypertrophic scar formation.
* Patients receiving treatment with systemic retinoids or having stopped their course since less than six months duration.
A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs

This study compares two different methods to prepare the uterine lining of recipients for implantation in cycles using donor eggs. The study method requires less time than the standard method.

It is hypothesized that both methods would be suitable for use in egg donor cycles.

Currently a combination of medications is used to prepare the uterine lining of recipients for implantation in egg donor cycles. The protocol used most commonly is as follows: Initially the individual's own pituitary-ovarian system is suppressed using a GnRH agonist so there are not conflicting signals sent to the uterus. This is followed by hormonal medication identical to what is secreted by the ovaries to prepare the uterine lining for subsequent embryo transfer in donor egg cycles.This preparation typically takes a minimum of four weeks.

This study will compare a different medication, a GnRh antagonist (which is commonly used in IVF) to suppress an individual's system during the preparation of the uterine lining. This protocol would generally take only two weeks to prepare the uterine lining.

Eligibility Criteria:
Inclusion Criteria:

* recipients awaiting egg donation
* some ovarian function
* normal endometrial cavity

Exclusion Criteria:

* submucosal myoma
* myoma(s) greater than 4 centimeters
* endometrial polyp
* DES exposure
* documented recalcitrant thin endometrium ( \<7 mm)
* untreated vulvovaginitis
* active pelvic infection
* endometrial cancer or suspected/known hormonally sensitive cancers
* breast cancer
* thromboembolic disease
* cerebrovascular or coronary heart disease
* diabetes mellitus
* hepatic tumors or active liver disease
* severe hypertension
* headaches with neurologic disease
* cholestatic disease
* heavy smoking over age 35
Effect of Anesthesia on Quality of Recovery in Patients Undergoing Correctional Tibial Osteotomy - A Randomized Controlled Trial

The effect of total intravenous anesthesia (TIVA) versus inhalational anesthesia on the quality of recovery from surgery has been reported in several different types of operations. The Quality of Recovery 40 (QoR-40) questionnaire is designed multi-dimensionally to assess the degree of recovery after anesthesia and surgery, and has been validated in previous studies. The present study aims to compare the quality of recovery with the QoR-40 questionnaire, in patients undergoing correctional tibial osteotomy under general anesthesia with either TIVA with propofol or inhalational anesthesia with desflurane.


Eligibility Criteria:
Inclusion Criteria:

1. Adult patients over the age of 19 scheduled for cosmetic lower limg lengthening for short stature, or correctional tibial osteotomy for osteoarthritis

Exclusion Criteria:

1. Patient refusal
2. Patients with altered mental status
3. Ejection fraction under 55%
4. Recent MI, CVA, or major cardiovascular surgery
5. 3rd degree AV block, 2nd degree AV block with P:QRS ration greater than 3:1
6. Hemodynamically unstable patients requiring vasopressors or oxygen therapy
7. Febrile patients
8. Patients with decreased renal function (serum Cr \> 0.1 mg/dL)
9. Patients with known allergies to propofol
10. Pregnant patients
Pharmacotherapy Follow-up in Older HIV-infected Patients

Cardiovascular diseases (CVD) are the main cause of death in Spain. In HIV patients, the uncontrolled viral replication, antiretroviral therapy (ART) and coinfections contribute to develop metabolic diseases and increase the prevalence of risk factors for CVD. These patients are aging which results in a higher probability of comorbidities, increased number of medications, possibility of having a negative outcome associated with medication (NOM) and increased cardiovascular risk (CVR). Various studies have established that pharmaceutical care (PC) results in better control of cardiovascular risk factors.

The purpose of this study is to evaluate the impact of pharmaceutical care achieved through pharmacotherapy follow-up on cardiovascular risk and health related quality of life (HRQoL) of HIV patients older than 50.

Quasi-experimental clinical study, pre-post intervention, performed with one patient cohort.

Study will be carry out at a tertiary hospital. The population will be constituted of patients who receive care from the outpatient department of the pharmacy service in use of antiretroviral therapy.

Variables will be obtained from patients' clinical histories, from dispensing records and through interviews with patients.

Main variables:

* cardiovascular risk estimated according to Systematic Coronary Risk Evaluation (SCORE) and Registre Gironí del Cor (REGICOR) equations
* HRQoL measured by the Short-Form 36-Item Health Survey (SF-36) and Medical Outcomes Study HIV Health Survey (MOS-HIV) questionnaires.

Other variables: sociodemographic, clinical, pharmacological, related to CVR, related to NOM and to the interventions.

Interventions will be performed every two months until complete 12 months of follow-up. Pharmacotherapy follow-up will be conducted according to the Dader method. The interventions will be health education for lifestyle modification, improve adherence and aimed to the resolution of NOM and drug-related problems.

Eligibility Criteria:
Inclusion Criteria:

* patients older than 50 years
* in use of antiretroviral therapy
* cardiovascular risk ≥2%, estimated by the SCORE equation
* accept to participate in the research through the signature of a written informed consent

Exclusion Criteria:

* patients with neurodegenerative deficit or HIV dementia
* participants in clinical trials
* non signature of a written informed consent
The Effect of Washback on Reading Comprehension

Testing and teaching are completely interrelated in education process; using various kinds of tests teachers are able to anticipate about the strong and weak points of learning in students, their progress and their accomplishment. The influence a test on teaching and learning is commonly referred to as washback. Testing washback is a twisted concept that becomes even more complex under a various interpretations of the washback phenomenon on teaching and learning. This study aimed to describe washback behaviors of students, in the low stakes testing in an ESP environment in two-fold. First, the study investigated the effects of different formative tests on Iranian medical students' English reading comprehension achievement. Secondly, the study explores the effects of washback on the students' attitudes toward English reading comprehension. The pre- and post-tests and one questionnaire were used to collect the data from Iranian medical students. Data were analyzed by paired t-test, t-test, and Mann-Whitney U test.


Eligibility Criteria:
Inclusion Criteria:

* nursing students
* study at mums

Exclusion Criteria:

* other disciplines
* study at other universities
Impact of a Nutritional Intervention on Type1 Diabetes Adult With Metabolic Syndrome

Recent studies have found that up to 45 % of patients with type 1 diabetes have metabolic syndrome, a cluster of conditions (abdominal obesity, hypertension, dyslipidemia, insulin resistance) that increase the cardiovascular risk. The investigators have observed in previous studies a strong association between the adherence to a Mediterranean diet and the prevalence of metabolic syndrome on patients with metabolic syndrome. However, no intervention has been realized on this population and the current recommendations (low fat diet) differ from the Mediterranean diet. A nutritional intervention on the principles of the Mediterranean diet could therefore play a role in the treatment of the metabolic syndrome in Type 1 diabetes patients. The main objective of this study is to examine the impact of a nutritional intervention on the waist circumference after 6 months of an intervention group (Mediterranean diet) versus a control group (low fat diet).


Eligibility Criteria:
Inclusion Criteria:

* Type 1 Diabetes for at least 12 months
* On intensive insulin therapy with multiple daily injections or on insulin pump
* Be overweight or obese (BMI≥25 kg/m2)
* Stable weight for at least 3 months
* If on medication for thyroid, hypertension or dislipidemia: stable doses in the last 3 months
* Presenting at least 3 of the 5 following criteria for metabolic syndrome:

  1. Waist circumference \>102cm ♂ or \>88cm ♀
  2. Triglycerides \>1.7mmol/L or medication
  3. Cholesterol-HDL \<1.0mmol/L ♂ or \<1.3mmol/L ♀ or medication
  4. Blood pressure ≥130/85 mmHg or medication
  5. Estimated insulin resistance (eGDR \<6.29)

Exclusion Criteria:

* Mental incapacity, refusal or linguistic barrier that could affect comprehension or cooperation with the study
* Ongoing pregnancy
* Diet corresponding to the criteria of a mediterranean diet (score≥27)
* Vegetarianism
* Major diabetes complications
Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer

RATIONALE: A low-fat, balanced diet may prevent disease progression in patients with nonmelanomatous skin cancer.

PURPOSE: Randomized phase II trial to study the effectiveness of a low-fat, balanced diet to prevent disease progression in patients with nonmelanomatous skin cancer.

OBJECTIVES: I. Determine whether intervention with a low-fat balanced diet will prolong the disease-free survival time in patients presenting with nonmelanomatous skin cancer and having a history of not more than two previous skin cancers. II. Assess the effect of this intervention on numbers of tumors during the two year follow-up period. III. Determine the incidence of new skin cancer in the control, nonintervention population.

OUTLINE: This is a randomized study. Patients are randomized into the Dietary Intervention or Nonintervention groups. The control group has initial and follow up assessment of eating habits. The dietary intervention group also has initial and follow up assessment of eating habits that have been changed to reduce fat intake to one-half of the amount in the average American diet with a subsequent increase of carbohydrates to compensate for total caloric intake. Both groups have assessment of clinical status of skin cancer at 4 month intervals for 24 months. Patients are followed for two years.

PROJECTED ACCRUAL: Approximately 175 patients will be accrued in the first 3 years of this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed basal cell carcinoma or squamous cell carcinoma of the skin No more than two prior skin carcinomas Must not have genetic predisposition to skin cancer (i.e., xeroderma pigmentosum, basal cell nevous syndrome)

PATIENT CHARACTERISTICS: Age: 15 and over Race: Caucasian Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No therapeutic diet that requires fat intake greater than 20% of total calories No untreated systemic malignancy No history of arsenic ingestion Not diabetic

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: No concurrent systemic steroids Radiotherapy: No prior x-ray therapy for acne No prior/concurrent ultraviolet light (PUVA or UVB) therapy for psoriasis Surgery: Not specified Other: No concurrent megavitamin or mineral supplementation At least 5 years since treatment with antimetabolites, folic acid inhibitors, alkalating agents, etc.
Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion

The purpose of this study is to compare the success rate of letrozole and misoprostol versus misoprostol alone for medical termination of first trimester pregnancy.

Primary outcome:

Incidence of complete miscarriage (complete expulsion of the products of conception with no need for surgical intervention within one week from the first dose of misoprostol)

Secondary outcome:

Need for surgical evacuation of the products of conception

* Incomplete expulsion of the products of conception (incomplete miscarriage).
* Considerable bleeding necessitating immediate surgical evacuation. Maternal morbidity
* Major side effects (Sepsis, considerable vaginal bleeding leading to hemodynamic instability or necessitating blood transfusion)
* Minor side effects (fever, rigors, nausea, vomiting) Patient's compliance and adherence to treatment Hemoglobin and hematocrit deficit

Eligibility Criteria:
Inclusion Criteria:

* Maternal age more than 18 years old (age of legal consent).
* Gestational age less than 13 weeks.
* Hemoglobin \>10 g/dL.
* BMI between 25 kg/m2 and 35 kg/m2.
* Missed abortion.
* Living fetus with multiple congenital malformations incompatible with life.

Exclusion Criteria:

* Maternal age less than 18 years old.
* Gestational age more than 12 weeks.
* Hemoglobin \<10 g/dL.
* Anencephaly.
* Fibroid uterus.
* BMI less than 25kg/m2 and more than 35kg/m2.
* Coagulopathy.
* History or evidence of adrenal pathology.
* Previous attempts for induction of abortion in the current pregnancy.
* Allergy to misoprostol or letrozole.
* Medical disorder that contraindicate induction of abortion (e.g. heart failure).
Oral-only Antibiotics for Bone and Joint Infections in Children

A nationwide, multicenter, randomized, non-inferiority trial of children with bone and joint infections. The primary objective is to determine if oral-only antibiotics (experimental arm) is non-inferior to initial intravenous antibiotics followed by oral therapy (control arm). Children will be randomized 1:1. The total treatment duration is identical in both groups. The study is open label with blinding of the primary endpoint assessor.


Eligibility Criteria:
Inclusion Criteria:

* Children aged 3 months to 18 years with antibiotic treatment of uncomplicated bone or joint infection.

Exclusion Criteria:

1. Severe disease, e.g. septic shock, or any concomitant infection, e.g. necrotizing fasciitis, requiring IV antibiotics in the opinion of the treating clinician.
2. Complicated bone or joint infection, e.g. prosthetic material, infection secondary to or complicated by trauma, severe pyomyositis or other substantial soft tissue infections.
3. Expected need of major surgery within the first 24 hours of treatment, e.g. drilling, debridement, fenestration, surgical drainage, synovectomy. Minor surgery as diagnostic surgical bone biopsy or diagnostic joint fluid aspiration including lavage is not a criterion for exclusion.
4. Significant co-morbidities that might influence the choice of treatment or the course of the infection, e.g. immunodeficiency, immunosuppressive therapy, sickle cell anemia.
5. Previous bone or joint infection.
6. Antibiotic therapy for more than 24 hours before inclusion.
7. Documented pathogen with limited treatment options that do not permit randomization, e.g. the pathogen is only sensitive to intravenous antibiotics.
8. Prior enrolment in the trial
Myocardial Blood Flow by 15O Water PET

Coronary heart disease is a very common condition caused by narrowings in the blood vessel supplying the heart. the investigators are studying new tests to diagnose heart disease. In this study the investigators plan to investigate a special scan called a PET/CT (Positron emission tomography/computed tomography) and a new type of CT (Computed tomography) scan to tell us about the flow of blood to the heart muscle.

Participants will undergo PET/CT with oxygen-15 labelled water and computed tomography myocardial perfusion imaging.

Eligibility Criteria:
Inclusion Criteria:

* suspected coronary artery disease

Exclusion Criteria:

* inability or unwillingness to undergo CT or PET imaging
* renal failure (serum creatinine \>200 um/L or eGFR \<30 ml/min)
* hepatic failure
* allergy to iodinated contrast
* pregnancy
* contraindication to adenosine
* inability to give informed consent
* atrial fibrillation with a fast ventricular rate (\>70 beats per minute)